IDiyas

For the Inventor, By the Inventor

London, United Kingdom

Matteo Righi

USPTO Granted Patents = 10 

 

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 13(Granted Patents)


Company Filing History:

goldMedal10 out of 53 
 
Autolus Limited
 patents

Years Active: 2020-2025

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents
1. 12234295 - Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof (2025-02-25),
2. 12187769 - Cell (2025-01-07),
3. 11701386 - Cell (2023-07-18),
4. 11648274 - Polypeptide (2023-05-16),
5. 11479614 - Methods for treating cancer or modulating T cells or NK cells in a subject with cancer by administering cells comprising chimeric cytokine receptors (2022-10-25),
6. 11479613 - Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteins (2022-10-25),
7. 11365262 - Cell (2022-06-21),
8. 11242377 - Chimeric receptor with ligand binding exodomain and cytokine and T cell signalling endodomains (2022-02-08),
9. 10800855 - Chimeric cytokine receptors and encoding nucleic acids (2020-10-13),
10. 10800854 - Chimeric cytokine receptors and encoding nucleic acids (2020-10-13),

Title: The Innovative Contributions of Matteo Righi

Introduction

Matteo Righi is a prominent inventor based in London, GB, known for his significant contributions to the field of biotechnology. With a total of 10 patents to his name, Righi has made remarkable advancements in the development of chimeric proteins and cell-based therapies. His work has the potential to revolutionize treatments for various diseases.

Latest Patents

One of Righi's latest patents is focused on a chimeric transmembrane protein that comprises antibody dimerization domains and a type I cytokine receptor endodomain. This invention provides a chimeric cytokine receptor (CCR) that includes an exodomain capable of binding to ligands such as tumor-secreted factors, chemokines, and cell-surface antigens. Additionally, he has developed a patent related to a cell that incorporates a chimeric antigen receptor (CAR) along with a constitutively active or inducible Signal Transducer and Activator of Transcription (STAT) molecule.

Career Highlights

Righi's career is marked by his innovative research and development efforts at Autolus Limited, a company dedicated to advancing cell and gene therapies. His expertise in creating novel therapeutic solutions has positioned him as a key figure in the biotechnology sector.

Collaborations

Throughout his career, Righi has collaborated with notable colleagues, including Martin Pulé and Shaun Cordoba. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in their field.

Conclusion

Matteo Righi's contributions to biotechnology through his patents and collaborative efforts highlight his role as an influential inventor. His work continues to pave the way for innovative therapies that could significantly impact patient care in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…